Therapy News and Research

RSS

Wyeth Pharmaceuticals receives FDA approvable for Bazedoxifene for the prevention of postmenopausal osteoporosis

Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for bazedoxifene, a selective estrogen receptor modulator (SERM) for the prevention of postmenopausal osteoporosis.

26 Apr 2007

Evaluation of primary urinary tract infection in infants

They reviewed the clinical and laboratory findings as well as the diagnosis and treatment. This study is important since urinary tract infection is one of the most common causes of unexplained fevers in infants with an overall reported prevalence of approximately 10%. infection.

25 Apr 2007

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

25 Apr 2007

Moonlighting enzyme linked to Friedreich's ataxia

Friedreich's ataxia is one of those diseases few have heard of unless you know someone with the condition.

25 Apr 2007

Succimer therapy improves balance and movement in lead-exposed children

University of Cincinnati (UC) environmental health researchers say a therapy commonly used to remove dangerously high levels of lead from the body may also improve muscle functions associated with postural balance and movement in lead-exposed children.

25 Apr 2007